FDA Orphan Disease Clinical Trial Grants Aim To Reduce Financial Risk
Agency awards $22m to support 15 clinical trials and approximately $10m for six natural history studies in rare diseases. FDA Commissioner Gottlieb highlights the program as a way for the agency to help de-risk clinical development.
You may also be interested in...
US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.